Pharma BD Deal Intelligence
A mid-cap merger of equals that made Pharmacia's Celebrex and Xalatan the growth story while Monsanto's Roundup and biotech assets rode along—until the ag division proved a poor fit and was spun back out as its own company, undoing the deal's logic within a few years.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pharmacia & Upjohn and Monsanto merged in a $27 billion stock-for-stock merger of equals, creating Pharmacia Corporation with a combined market capitalization exceeding $50 billion. Each Pharmacia share was exchanged for 1.19 shares and each Monsanto share for 1 share of the new entity. The agricultural division was later spun off as a separate Monsanto.
20M US cases/yr · $7.0B Global Anti-Arthritis Drug Market (1999) · 60% US Arthritis Patients on COX-2 Inhibitors (peak)
Arthritis affects ~54M US adults, with osteoarthritis (cartilage degeneration and subchondral bone remodeling) the most common form at ~32M cases, followed by rheumatoid arthritis (autoimmune synovitis). Symptoms include joint pain, stiffness, and reduced range of motion; progression can cause disability and is a leading cause of work limitation in US adults.
Celebrex launched in early 1999 and immediately dominated the pain market, competing directly with Merck's Vioxx (launched May 1999). At peak, 60% of US arthritis patients used COX-2 inhibitors. The class was devastated when Vioxx was withdrawn in 2004 over cardiovascular risk, but Celebrex survived and remained a multi-billion dollar franchise.
2.7M US cases/yr · $3.0B Global Glaucoma Drug Market (1999)
Glaucoma is a group of optic neuropathies causing progressive irreversible vision loss, most commonly primary open-angle glaucoma. Approximately half of affected patients are undiagnosed because early disease is asymptomatic; vision loss begins in the peripheral field. Elevated intraocular pressure is the principal modifiable risk factor, and IOP-lowering therapy slows progression.
Xalatan dominated the glaucoma market through the early 2000s as the first-in-class prostaglandin analog. Competitors included Alcon's Travatan (travoprost) and Allergan's Lumigan (bimatoprost). The Pharmacia-Monsanto merger brought Xalatan into the same portfolio as Celebrex, creating a diversified pharma powerhouse that Pfizer would ultimately acquire in 2003.
Pharmacia & Upjohn and Monsanto announce $27B all-stock merger of equals to combine pharma (Celebrex/Searle) with agricultural biotech, creating Pharmacia Corporation.
Both Pharmacia & Upjohn and Monsanto shareholders vote to approve the merger at special meetings, clearing a key governance hurdle.
European Commission approves the Monsanto/Pharmacia & Upjohn merger subject to divestiture conditions in the seed treatment market.
Merger completes forming Pharmacia Corporation, combining Searle pharma (Celebrex, Bextra) with Monsanto agricultural biotech assets.
Pharmacia IPOs 15% of the new Monsanto agricultural business, beginning the planned full separation of the ag-biotech unit from the pharma core.
Pfizer announces $60B acquisition of Pharmacia Corporation, ultimately absorbing the Celebrex/Searle franchise that was the strategic rationale for the original merger.
Pharmacia board approves and completes full spin-off of remaining Monsanto shares, making Monsanto an independent ag-biotech company and leaving Pharmacia as a pure pharma player.
The merger was a temporary holding structure. The pharma-ag conglomerate logic never held; Monsanto was spun off within two years and Pharmacia itself was absorbed by Pfizer. Celebrex justified the deal but Bextra/Vioxx-class risks emerged later. Net: facilitated industry consolidation but created no lasting standalone entity.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pharmacia & Upjohn Inc. / Monsanto Company (this deal) | 1999 | $27.0B | 64 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 1999 deals · Immunology deals